Back to search

National and Kapodistrian University of Athens

Η Ρεγαδενοσόνη (Regadenoson) ως φαρμακολογικός παράγοντας κόπωσης για τη σπινθηρογραφική απεικόνιση της αιμάτωσης του μυοκαρδίου σε ασθενείς, υποψήφιους για ενδιάμεσου έως υψηλού κινδύνου μη-καρδιακή επέμβαση: συγκριτική μελέτη με διπυριδαμόλη

Abstract

dc:description

Introduction: Dipyridamole is the oldest coronary vasodilator approved by the Food and Drug Administration (FDA), used for pharmacologic stress during myocardial perfusion scintigraphy. It indirectly causes vasodilation by increasing circulating adenosine levels. Regadenoson, on the other hand, is the first FDA-approved selective agonist for A2A adenosine receptors, responsible for coronary vasodilation. Its main benefits are its simplified and brief protocol, along with the ability to be administered safely in patients with asthma or chronic obstructive pulmonary disease of moderate severity. The present study aims to identify any potential benefits of regadenoson, regarding the frequency of adverse reactions and its tolerability, over dipyridamole.Methods: This is a randomized controlled study of 200 patients scheduled for medium to high-risk non-cardiac surgery, of which 100 have been stressed with regadenoson (study group) and the rest with dipyridamole (control group).Results: A greater proportion of adverse reactions was recorded in the regadenoson group as compared to the dipyridamole group (53% vs. 36%), although the duration of most was shorter in the regadenoson group. Dyspnea (p<0,001) and gastrointestinal disturbances (p=0,001) were significantly more frequent in the regadenoson group. The use of aminophylline in patients who presented any adverse reactions was similar in the two groups (p>0,05). After multiple logistic regression analysis, differences in the frequency of adverse reactions, taken as a whole, between the two groups were no longer significant (odds ratio = 1,96, 95% confidence interval = 0,88-3,25). p=0,11).Conclusion: In our group of patients scheduled for myocardial perfusion imaging for preoperative assessment, the two agents, regadenoson and dipyridamole, had no significant differences in the frequency of mild adverse reactions and aminophylline administration, with regadenoson also having the advantage of faster symptom resolution. Nevertheless, dipyridamole can still be considered as a low-cost and safe alternative.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2022

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Stavrou, Petros
  • Σταύρου, Πέτρος

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/52249

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Stavrou, Petros; Σταύρου, Πέτρος. Η Ρεγαδενοσόνη (Regadenoson) ως φαρμακολογικός παράγοντας κόπωσης για τη σπινθηρογραφική απεικόνιση της αιμάτωσης του μυοκαρδίου σε ασθενείς, υποψήφιους για ενδιάμεσου έως υψηλού κινδύνου μη-καρδιακή επέμβαση: συγκριτική μελέτη με διπυριδαμόλη. National and Kapodistrian University of Athens, 2022. http://hdl.handle.net/10442/hedi/52249